Based on the recent earnings call, it is evident that the company has achieved impressive financial results and has a positive outlook for the coming year. The Q4 revenue grew by 5% year-over-year, reaching $619 million. The company saw substantial growth in consumable revenue, with sequencing consumable revenue growing by 20% year-over-year to $331 million. Additionally, services and other revenue equaled $94 million.

The adjusted gross margin for the fourth quarter was 69.9%, which was lower sequentially due to various factors, including product transition reserves and scaled manufacturing operations. However, the company expects margins to be roughly flat sequentially in the coming year.

The company's adjusted research and development expenses in Q4 were $121 million, an increase of $7 million over Q3, and adjusted SG&A expenses for the quarter equaled $130 million, an increase of $13 million sequentially.

In terms of guidance, the company is projecting Q1 revenue of $580 million to $595 million and total company revenue expected to grow 10% to 12% in 2017. The company expects Q1 GAAP earnings per diluted share of $0.51 to $0.56 and non-GAAP earnings per diluted share of $0.60 to $0.65. For the full year, GAAP earnings per diluted share is expected to be $3.25 to $3.35 and non-GAAP EPS is expected to be $3.60 to $3.70.

Overall, based on the company's recent earnings call and its positive outlook for the coming year, it is recommended to take an 'overweight' investment stance on the company. The impressive revenue growth and solid financial performance indicate a strong potential for future returns.